Cardinal Health

F500 2019-Cardinal Health
Courtesy of Nick Collura/Cardinal HealthCourtesy of Nick Collura/Cardinal Health
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

The $136.8 billion revenue drug wholesaler and medical supplier managed 5.3% sales growth in 2018 despite an increasingly challenging environment largely due to greater sales of high-price drugs used in oncology, among other medical specialties. The bulk of Cardinal’s revenue comes from the medications it distributes to pharmacies and is impacted by fluctuations in drug prices. The declining price of generics has weighed on the company's bottom line in recent years and the heightened scrutiny of drug pricing has created uncertainty for Cardinal and its two bigger rivals, McKesson and AmerisourceBergen. The industry is also under continued pressure—and faces a growing number of lawsuits—over its alleged role in the nation’s opioid epidemic.

Company Info

CEOMichael C. Kaufmann
CEO TitleChairman & Chief Executive Officer
SectorHealth Care
IndustryWholesalers: Health Care
HQ LocationDublin, Ohio
Years on Fortune 500 List25

Key Financials (Last Fiscal Year)

Revenues ($M)$136,809
Profits ($M)$256
Assets ($M)$39,951
Total Stockholder Equity ($M)$6,059

Profit Ratios

Profit as % of Revenues0.2%
Profits as % of Assets0.6%
Profits as % of Stockholder Equity4.2%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)81
EPS % Change (from 2017)-79.9%
EPS % Change (5 year annual rate)-3.5%
EPS % Change (10 year annual rate)-13.8%

Total Return

Total Return to Investors (2018)-24.8%
Total Return to Investors (5 year, annualized)-5.6%
Total Return to Investors (10 year, annualized)8.4%